Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update

Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 19,900,000 shares, a decrease of 9.3% from the October 15th total of 21,940,000 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is presently 8.3 days.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 30,401 shares of company stock valued at $352,038 over the last quarter. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors have recently bought and sold shares of the business. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $26,000. Hazlett Burt & Watson Inc. raised its position in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. lifted its stake in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new stake in shares of Amicus Therapeutics in the third quarter worth about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $55,000.

Amicus Therapeutics Trading Down 2.3 %

Shares of NASDAQ:FOLD traded down $0.22 during trading on Tuesday, reaching $9.44. 897,177 shares of the stock were exchanged, compared to its average volume of 2,718,011. The firm’s 50-day moving average price is $10.96 and its 200 day moving average price is $10.61. Amicus Therapeutics has a 12-month low of $9.02 and a 12-month high of $14.57. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

Analyst Upgrades and Downgrades

Several analysts have commented on FOLD shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. increased their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Morgan Stanley lowered their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Finally, Cantor Fitzgerald upped their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.63.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.